[go: up one dir, main page]

AR121715A1 - Pirrolopirimidinaminas como inhibidores del sistema del complemento - Google Patents

Pirrolopirimidinaminas como inhibidores del sistema del complemento

Info

Publication number
AR121715A1
AR121715A1 ARP210100817A ARP210100817A AR121715A1 AR 121715 A1 AR121715 A1 AR 121715A1 AR P210100817 A ARP210100817 A AR P210100817A AR P210100817 A ARP210100817 A AR P210100817A AR 121715 A1 AR121715 A1 AR 121715A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
independently
optionally substituted
instance
Prior art date
Application number
ARP210100817A
Other languages
English (en)
Inventor
Pravin L Kotian
Yarlagadda S Babu
Minwan Wu
zhao Dang
Trung Xuan Nguyen
Krishnan Raman
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of AR121715A1 publication Critical patent/AR121715A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compuestos de fórmula (1) y sus sales farmacéuticamente aceptables, que son inhibidores del sistema del complemento. También, composiciones farmacéuticas que comprenden un compuesto con dichas características y métodos para usar los compuestos y composiciones en el tratamiento o la prevención de una enfermedad o condición caracterizada por una actividad aberrante del sistema del complemento. Reivindicación 1: Un compuesto caracterizado porque se representa por medio de la fórmula (1), o una sal farmacéuticamente aceptable del mismo; donde, en forma independiente en cada instancia: X es una unión o C(RX)₂; Y es una unión, C(RY)₂, o -N(Rᵇ)-; G es S o C(R³)₂; Rᵃ y Rᵇ son en forma independiente entre sí H o (C₁-C₆)alquilo; R¹ representa arilo, heteroarilo, alquilo, cicloalquilo, alquenilo, o cicloalquenilo opcionalmente sustituido; R² representa heteroarilo bicíclico o tricíclico opcionalmente sustituido; R³ es en forma independiente en cada instancia H, halógeno, -CN, -NH₂, -CH₂NH₂, (C₁-C₆)alcoxi o (C₁-C₆)alquilo; o dos instancias vecinales de R³ tomadas junto con los átomos de carbono a los que están unidas forman un (C₃-C₇)cicloalquilo o (C₆)arilo fusionado opcionalmente sustituido; o dos instancias geminales de R³ tomados junto con el átomo de carbono al que están unidos forman un (C₃-C₇)cicloalquilo espiro opcionalmente sustituido; o dos instancias hominales de R³ tomadas junto con los átomos de carbono a los que están unidas forman un (C₃-C₇)cicloalquilo en puente opcionalmente sustituido; RX es en forma independiente en cada instancia H, (C₁-C₆)alquilo, o (C₃-C₇)cicloalquilo; RY es en forma independiente en cada instancia H, (C₁-C₆)alquilo, o (C₃-C₇)cicloalquilo; o una instancia de RY y un sustituyente sobre R² tomados junto con los átomos intermedios forman un anillo; los sustituyentes opcionales sobre R¹ o R² en forma independiente en cada caso representan halógeno, -CN, -NO₂, -OR¹³, -NR¹³R¹⁴, -C(O)R¹³, -C(O)OR¹³, -C(O)NR¹³R¹⁴, -OC(O)R¹³, -NR¹³C(O)R¹⁴, -OC(O)NR¹³R¹⁴, -OC(O)OR¹³, -NR¹³C(O)OR¹⁴, -NR¹³C(O)NR¹³R¹⁴, -OS(O)ₚ(R¹³), -SR¹³, -NR¹³S(O)ₚ(R¹⁴), o alquilo, alquenilo, alquinilo, haloalquilo, hidroxialquilo, alcoxialquilo, cicloalcoxialquilo, ariloxialquilo, aralquilo, heteroaralquilo, heteroarilo, arilo, ariloxi, cicloalquilo, (cicloalquil)alquilo, heterocicloalquilo, o (heterocicloalquil)alquilo opcionalmente sustituido; o donde dos sustituyentes sobre R¹ o dos sustituyentes sobre R², tomados junto con los átomos intermedios, forman un anillo; R¹³ y R¹⁴, en forma independiente en cada instancia, representan H o alquilo, haloalquilo, alquenilo, alquinilo, arilo, o heteroarilo opcionalmente sustituido; y p es 0, 1, ó 2.
ARP210100817A 2020-04-03 2021-03-31 Pirrolopirimidinaminas como inhibidores del sistema del complemento AR121715A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063004799P 2020-04-03 2020-04-03

Publications (1)

Publication Number Publication Date
AR121715A1 true AR121715A1 (es) 2022-06-29

Family

ID=77929437

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100817A AR121715A1 (es) 2020-04-03 2021-03-31 Pirrolopirimidinaminas como inhibidores del sistema del complemento

Country Status (23)

Country Link
US (1) US20230159536A1 (es)
EP (1) EP4125914A4 (es)
JP (1) JP2023519824A (es)
KR (1) KR20220163955A (es)
CN (1) CN115427044A (es)
AR (1) AR121715A1 (es)
AU (1) AU2021246098A1 (es)
BR (1) BR112022018067A2 (es)
CA (1) CA3176808A1 (es)
CL (1) CL2022002649A1 (es)
CO (1) CO2022015630A2 (es)
CR (1) CR20220553A (es)
CU (1) CU20220060A7 (es)
DO (1) DOP2022000211A (es)
EC (1) ECSP22085221A (es)
IL (1) IL296978A (es)
JO (1) JOP20220227A1 (es)
MX (1) MX2022012056A (es)
PE (1) PE20230601A1 (es)
TN (1) TN2022000255A1 (es)
TW (1) TW202204358A (es)
UY (1) UY39150A (es)
WO (1) WO2021202977A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024538175A (ja) * 2021-10-18 2024-10-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド ループス腎炎及び免疫グロブリンａ腎症の治療のための補体ｄ因子阻害剤の使用
WO2024008121A1 (zh) * 2022-07-06 2024-01-11 南京明德新药研发有限公司 二氟取代的氮杂双环化合物及其应用
WO2024047078A1 (en) * 2022-09-01 2024-03-07 F. Hoffmann-La Roche Ag Dosage regimen of vicasinabin
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
US11964981B1 (en) 2023-09-18 2024-04-23 King Faisal University Substituted pyrimido[4,5-b]indoles as CK2 inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
JPH05502179A (ja) 1990-02-28 1993-04-22 メドトロニック　インコーポレーテッド 管状器官内薬剤溶出装具
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
EP1144373B1 (en) 1999-01-13 2005-10-19 Genentech, Inc. Serine protease inhibitors
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
ES2647664T3 (es) * 2011-01-04 2017-12-26 Novartis Ag Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (AMD)
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035348A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of medical disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
TWI854164B (zh) 2016-02-01 2024-09-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
IL303696B2 (en) 2017-03-01 2025-02-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018229543A2 (en) 2017-06-14 2018-12-20 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
IL277787B2 (en) 2018-04-06 2024-02-01 Biocryst Pharm Inc Benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors are converted

Also Published As

Publication number Publication date
EP4125914A4 (en) 2024-07-03
UY39150A (es) 2021-10-29
JOP20220227A1 (ar) 2023-01-30
EP4125914A1 (en) 2023-02-08
JP2023519824A (ja) 2023-05-15
CN115427044A (zh) 2022-12-02
DOP2022000211A (es) 2022-11-15
AU2021246098A1 (en) 2022-10-20
MX2022012056A (es) 2022-10-13
ECSP22085221A (es) 2022-12-30
TW202204358A (zh) 2022-02-01
CA3176808A1 (en) 2021-10-07
CU20220060A7 (es) 2023-05-11
TN2022000255A1 (en) 2024-04-01
PE20230601A1 (es) 2023-04-10
WO2021202977A1 (en) 2021-10-07
CL2022002649A1 (es) 2023-05-26
KR20220163955A (ko) 2022-12-12
IL296978A (en) 2022-12-01
CO2022015630A2 (es) 2022-11-29
CR20220553A (es) 2023-02-03
BR112022018067A2 (pt) 2022-10-25
US20230159536A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
AR121715A1 (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
AR114044A1 (es) Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR107488A1 (es) Compuestos de benzopirazol y análogos de éstos
AR115646A1 (es) Inhibidores de quinasas dependientes de ciclinas
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
AR103252A1 (es) Compuestos de quinazolina
AR112216A1 (es) Derivados de azaquinolina
AR103297A1 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
CY1122201T1 (el) Παραγωγα βενζοδιοξολιου ως αναστολεις φωσφοδιεστερασης
AR080779A1 (es) Pirrolopirazina como inhibidores quinasa, composiciones farmaceuticas que los contienen y sus aplicaciones
AR105893A1 (es) Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR076264A1 (es) Triazolopiridinas sustituidas y analogos de estas
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
AR091193A1 (es) HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
PH12016501891A1 (en) Dihydrothiazine and dihydrooxazine derivatives having bace1 inhibitory activity
AR086636A1 (es) Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
AR080699A1 (es) Pirrolopirazinas como inhibidores de jak y syk
PE20160992A1 (es) Inhibidores de quinasa relacionada con la tropomiosina (trk)
CY1119118T1 (el) Θεραπευτικος παραγων για τις διαταραχες της διαθεσης